You have read all your free articles, to continue reading subscribe to read the rest of this content.
Targovax’s ONCOS-102 mesothelioma 12-month data demonstrate broad immune activation linked to clinical benefit and the company announces a new collaboration with Merck. Targovax has released 12-month efficacy and immunological data from the randomized phase I/II trial of ONCOS-102 in combinatioAlready a subscriber Login You have read all your free articles,…
Vaccibody expands the utilization of its technology platform into the area of infectious diseases in order to explore opportunities in this field of significant unmet medical needs. Dr. Gunnstein Norheim, former Director of Vaccine Science at Coalition for Epidemic Preparedness Innovations (CEPI)Already a subscriber Login You have read all your…
InDex Pharmaceuticals Holding has received positive responses from FDA and EMA regarding its phase III development of the TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis. Following the phase IIb study CONDUCT meeting its primary endpoint in August 2019, dialogAlready a subscriber Login You have read…
Ultomiris has been approved for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease. “Since bringing forward thefirst complement inhibitor, we’ve continuedAlready a subscriber Login You have read all your free articles, to continue…
